Printer Friendly

Group A streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011.

Streptococcus pyogenes, also known as group A Streptococcus (GAS), is a common human pathogen that can induce a wide spectrum of diseases, ranging from noninvasive diseases, such as pharyngitis, scarlet fever, and impetigo, to invasive diseases, such as erysipelas, cellulitis, pneumonia, bacteremia, necrotizing fasciitis, and toxic shock syndrome. Moreover, GAS can cause rheumatic fever and acute poststreptococcal glomerulonephritis (1,2). In the late 1980s, a change in the epidemiology of invasive GAS diseases and the emergence of streptococcal toxic shock syndrome were documented (3,4), and the current number of invasive GAS disease cases worldwide is high (2).

Many virulence factors contribute to the pathogenesis of GAS diseases (1,5). However, the matrix (M) protein, encoded by the emm gene, has the most critical role, mainly by antiphagocytic mechanisms (6,7), and the amino-terminal region of M protein is the most promising target for designing a vaccine (8,9). emm gene sequencing is a standard method for typing the M protein (10), but the distribution of emm types varies greatly by geographic location, time, and collection site of clinical specimens (9,11-14).

Streptococcal pyrogenic exotoxins also play a major role in the pathogenesis of GAS infections by acting as superantigens. When these exotoxins cross-link major histocompatibility complex class II molecules and T cell receptors, they trigger intense activation of a subset of T cells within a specific b-chain variable region. This process induces a tremendous release of a series of cytokines and may lead to cell, tissue, and organ damage (15,16).

Several antimicrobial drugs effectively treat GAS infections (1). In recent years, however, considerable attention has been given worldwide to the issue of antimicrobial drug-resistant GAS. Macrolide-resistant GAS strains have been isolated from various regions of the world (17-19). Macrolides are used as an alternative treatment for GAS in patients allergic to penicillin, and clindamycin, in combination with b-lactam antimicrobial drugs, is a recommended treatment for invasive GAS disease (20). Thus, it is critical that surveillance for macrolide- and clindamycin-resistant GAS be continued.

In China, scarlet fever is the only GAS disease reported by the National Notifiable Infectious Disease Surveillance System (NNIDSS) (21). According to NNIDSS, the incidence of scarlet fever in Beijing, China, before 2011 had persistently remained within normal threshold limits. However, in late spring 2011, an epidemic of scarlet fever occurred in Beijing and many other regions of China. In response to the epidemic, enhanced surveillance for GAS diseases was conducted in Beijing during May-July 2011 to determine characteristics of the circulating GAS strains.

Methods

National Notifiable Infectious Disease Surveillance System

China established NNIDSS in 2004, after the 2003 outbreak of severe acute respiratory syndrome. At that time, NNIDSS covered 37 infectious diseases, which were classified into 3 categories (A-C), in a descending order according to disease severity; scarlet fever belonged to category B.

A clinical case of scarlet fever is defined as acute illness onset with fever, pharyngitis, and sandpaper-like red rash with or without strawberry tongue, Pastia lines, or circumoral pallor. In China, clinicians and hospitals are to report clinical cases of scarlet fever to NNIDSS within 6 hours of diagnosis. To respond to the 2011 epidemic of scarlet fever and to monitor its severity, each clinical case of scarlet fever reported in Beijing was followed for 3 weeks after the onset of disease.

Enhanced Surveillance for GAS Diseases

Enhanced surveillance for GAS diseases was conducted in the pediatric clinics of 36 hospitals within Beijing's 18 districts during May-July 2011. The surveillance system was designed and managed by the Beijing Center for Disease Prevention and Control (Beijing CDC). The Beijing CDC laboratory and 18 collaborating district laboratories were involved. The study was approved by the Institutional Review Board and the Human Research Ethics Committee of Beijing CDC.

The surveillance included children with scarlet fever or pharyngitis diagnosed by clinicians in the surveillance hospitals. All children with scarlet fever were invited to participate in the study after their parent(s)/guardian(s) gave informed consent. Each week, 10 children with pharyngitis were randomly selected from each hospital to participate in the study. Trained clinic staff used a standardized questionnaire to collect information (e.g., sex, age, date of illness onset, date medical care was sought, clinical symptoms and signs, and antimicrobial drug treatment) for each study participant. In addition, at each clinic, trained personnel obtained pharyngeal swab samples from study participants, and, the same day, a designated hospital staff member collected and sent all specimens to the corresponding district laboratory. The collaborating district laboratories isolated and identified GAS strains and then sent the isolates to Beijing CDC for emm typing, superantigen determination, and antimicrobial drug susceptibility testing. Patients with scarlet fever or pharyngitis from whom GAS was isolated were identified as confirmed GAS patients.

Isolation and Identification of GAS Strains

After pharyngeal swab samples arrived at a collaborating district laboratory, they were immediately spread onto 5% sheep blood agar plates and incubated overnight at 37[degrees]C in 5% CO2. We tested b-hemolytic isolates for susceptibility to bacitracin and used the Streptococcal Grouping Kit (Oxoid Ltd., Basingstoke, UK) to determine the Lancefield group for each isolate.

emm Typing

All GAS isolates were subjected to emm typing, as described (22). We extracted DNA and amplified and sequenced the 5' region of the emm gene by using recommended primers and cycling conditions (22). We aligned the sequence of the 5' region of the emm gene with sequences in the Blast-emm database (www.cdc.gov/ncidod/ biotech/strep/strepblast.htm; Centers for Disease Control and Prevention, Atlanta, GA, USA). The emm type and subtype of GAS isolates were identified on the basis of the 90 bases encoding the N terminal 30 residues of the processed M protein and the exact 150 base sequences encoding the N terminal 50 residues of the mature M protein, respectively. The fairly conserved 30 bases encoding the last 10 residues of the M protein signal sequence were referred to for identifying the start of the sequence encoding the mature M protein.

Superantigen Detection

Thirteen superantigens (speA-speC, speF-speM, smeZ, and ssa) were detected by subjecting each GAS isolate to real-time PCR. Specific PCR primers were used to amplify the gene of each superantigen in a 40-mL real-time PCR reaction system under the following cycling condition: 2 min at 94[degrees]C, followed by 40 cycles of 15 s at 93[degrees]C and 60 s at 55[degrees]C. Superantigen profiles were investigated for various emm types of GAS isolates.

Antimicrobial Drug Susceptibility Testing

We used the VITEK2 Compact (bioMerieux, Marcy l'Etoile, France) to test all GAS isolates for susceptibility to penicillin, ampicillin, quinupristin-dalfopristin, linezolid, vancomycin, tigecycline, levofloxacin, erythromycin, clindamycin, and tetracycline. We estimated the minimal inhibitory concentration of each antimicrobial drug for individual GAS isolates and determined the corresponding susceptibility according to the 2011 criteria of the Clinical and Laboratory Standards Institute (23).

Statistical Analysis

We entered data by using Microsoft Excel 2003 software (Microsoft Corp., Redmond, WA, USA) and analyzed data by using the SPSS 16.0 statistical package (SPSS Inc., Chicago, IL, USA). The mean and SD were calculated for continuous variables, and percentages were calculated for categorical variables. Differences in distributions of emm types and superantigens of GAS isolates were compared between subgroups of participants by using the [chi square] test or Fisher exact test. In addition, we compared antimicrobial drug susceptibilities by strain emm type by using the [chi square] test. We used multivariate unconditional logistic regression analyses to determine factors associated with various clinical signs of scarlet fever in patients with confirmed GAS infection. All statistical tests were 2-sided, and statistical significance was defined as p<0.05.

Results

Comparison of the 2011 Epidemic and 2006-2010 Cluster Outbreaks

According to NNIDSS, the annual number of scarlet fever cases in Beijing during 2006-2010 ranged from 1,193 to 2,264, and annual incidence rates ranged from 7.0 cases to 14.3 cases/100,000 population. In 2011, however, the number of scarlet fever cases in Beijing rose to 6,152, and the incidence rate rose to 31.4 cases/100,000 population. Peak monthly incidence rates in 2011 were 2.9-6.7 times those in 2006-2010. During the epidemic and during 2006-2010, scarlet fever cases peaked twice yearly: 1 peak occurred in early summer, and a second, less pronounced peak occurred in winter, except in 2010, when the winter peak was more pronounced (Figure, panel A).

Scarlet fever primarily affected children 3-8 years of age during the epidemic and nonepidemic years (Figure, panel B). During these years, the ratio of males to females in Beijing was 1.5:1.8, respectively, and the annual incidence of scarlet fever was persistently higher among males than females (Figure, panel C).

In Beijing, a cluster of scarlet fever was defined as onset of [greater than or equal to] 2 clinical cases within a 7-day period in a school or kindergarten. According to this definition, 37-131 clusters (85-316 cases) occurred during 2006-2010 in Beijing, and 401 clusters (1,116 cases) occurred during 2011. In addition, case-patient follow-up showed that all cases reported during May-December, 2011, were fully resolved 3 weeks after illness onset without complications.

[FIGURE OMITTED]

Characteristics of Children Enrolled in Enhanced Surveillance

A total of 3,359 children, representing 972 clinical cases of scarlet fever and 2,387 cases of pharyngitis, were enrolled in enhanced surveillance for GAS disease. Of the 3,359 enrollees, [approximately equal to] 41.0% were female. The mean age was 5.8 years (SD [+ or -] 3.3 years). The mean interval from illness onset to first medical visit was 1.5 days (SD [+ or -] 1.5 days). Approximately 41.2% of the children received antimicrobial drugs at home before seeking medical care.

Of the 3,359 enrollees, 647 (19.2%) were confirmed to have GAS infection. GAS was isolated from clinical samples for 44.2% (430/972) of the children with scarlet fever and from 9.1% (217/2,387) of the children with pharyngitis.

emm Subtypes and Superantigens

emm12 type accounted for 76.4% (494/647) of all GAS isolates. The leading emm subtypes were emm12.0 (65.7%), emm1.0 (16.8%), emm12.19 (5.7%), and emm12.1 (2.5%). There was a statistically significant difference in the proportion of emm 12 type GAS in children [less than or equal to] 5 years of age and those >5 years of age (p = 0.004) and in the proportion of emm1 scarlet fever cases and pharyngitis cases (p = 0.042) (Table 1).

All of the GAS isolates harbored speB, and almost all possessed speC, speF, speG, smeZ, and ssa. Approximately 20% of the isolates harbored speA or speJ, and [approximately equal to] 75% possessed speH or speI; however, the percentage of isolates that harbored speK, speL, or speM was extremely low (Table 1). A total of 25 profiles of superantigens were found in the GAS isolates. Of the 494 emm 12 isolates, 411 (83.2%) had the following superantigen profile: speA (-), speB (+), speC (+), speF (+), speG (+), speH (+), speI (+), speJ (-), speK (-), speL (-), speM (-), smeZ (+), ssa (+). Of the 111 emm1 isolates, 93 (83.8%) had the following superantigen profile: speA (+), speB (+), speC (+), speF (+), speG (+), speH (-), speI (-), speJ (+), speK (-), speL (-), speM (-), smeZ (+), ssa (+).

Antimicrobial Drug Susceptibility

All GAS strains isolated during the scarlet fever epidemic were susceptible to penicillin, ampicillin, quinupristin-dalfopristin, linezolid, vancomycin, and tigecycline, and 96.6% of them were susceptible to levofloxacin. Resistance to erythromycin, tetracycline, and clindamycin was found in 96.1%, 93.7%, and 79.4% of the isolates, respectively. A statistically significant difference was found between the percentage of emm1 and emm 12 strains resistant to clindamycin (87.4% vs. 77.9%, respectively; p = 0.025) but not between the percentage of those resistant to erythromycin (99.1% vs. 96.4%, respectively; p = 0.134) or tetracycline (97.3% vs. 93.1%, respectively; p = 0.097).

Factors Associated with Clinical Signs of Scarlet Fever

The odds of having strawberry tongue was higher for GAS-infected study participants [less than or equal to] 5 years of age (odds ratio [OR] 2.04, 95% CI 1.46-2.83; p < 0.001). The odds of having a red rash was higher for participants infected with an emm1 versus emm12 type strain (OR 1.63, 95% CI 1.01-2.62; p = 0.046) and for participants [less than or equal to] 5 years of age (OR 2.52, 95% CI 1.74-3.65; p<0.001). Compared with patients with emm12 type strains, those with emm1 type strains had a higher probability of having Pastia lines (OR 1.80, 95% CI 1.02-3.16; p = 0.043) or circumoral pallor (OR 2.15, 95% CI 1.17-3.93; p = 0.013) (see Table 2, Appendix, wwwnc.cdc.gov/EID/article/19/6/12-1020-T1. htm, for details).

Discussion

We found that an epidemic of scarlet fever occurred in Beijing in 2011. emm12 was the predominant type among the circulating GAS strains, and resistance to erythromycin, tetracycline, and clindamycin was high among the isolates.

Although the incidence of scarlet fever in Beijing in 2011 was much higher than that in preceding years, the basic characteristics, including the seasonality of epidemic peaks, the most vulnerable age group, and the difference in susceptibility to infection by sex, did not change. In Beijing, the incidence of scarlet fever usually peaks twice a year in 2 distinct seasons-summer and winter-with the highest peak in early summer; however, it is well-recognized that scarlet fever most commonly occurs in winter/spring in other locations (24,25). This finding indicates that in China, GAS is transmitted more easily in early summer than in winter, possibly because in early summer, compared with winter, each year an emm type that is relatively new to young children sweeps through a population of children that does not have an effective level of population immunity. In addition, the winter peak in 2010 was higher than the summer peak, which implies that this epidemic of scarlet fever started at the end of 2010.

Among the GAS strains we identified circulating in Beijing during 2011, types emm12 and emm1 were most predominant ([approximately equal to] 76% and [approximately equal to] 17%, respectively); these percentages were higher ([approximately equal to] 40%) and lower (>40%), respectively, than those reported in China during previous years (13,26,27). Scarlet fever outbreaks also occurred in Hong Kong and Shanghai, China, during 2011, and emm 12 was the predominant circulating type (28-30). These findings suggest that some intrinsic factors might have facilitated the spread of emm12 strains and led to the epidemic. Two previously unreported genomic insertions (64.9 kb and 46.4 kb) were identified in emm 12 GAS strains isolated during the 2011 scarlet fever outbreak in Hong Kong. However, analysis of emm12 strains isolated during 2005-2010 showed that the insertions were also present in those strains (28), and the study concluded that mobile genetic elements, environmental factors, and host immune status might have contributed to the 2011 scarlet fever outbreak in Hong Kong.

emm12 is not known to be the exclusively predominant GAS type in other countries (9,31,32), but it is possible that the emm12 type strains circulating in China in 2011 could spread to other regions. Therefore, surveillance for the increased presence of emm 12 strains outside of China is warranted. A 30-valent GAS vaccine that contains the most prevalent emm types found in our study (emm12 and emm1) is under development (8); such a vaccine would help prevent and control the spread of GAS diseases in China.

Superantigens in the GAS isolates in our study were similar to those found in isolates from other studies, except for speC and ssa. In contrast to findings in other studies, we found that almost all emm 1 GAS strains from the 2011 Beijing epidemic harbored speC, and ssa became the primary superantigen of emm1 and emm 12 isolates (11,32,33). Consistent with findings in earlier studies in other locations, we found that an extremely low number of GAS isolates harbored speK, speL, or speM (11,33,34).

All GAS isolates from the 2011 Beijing epidemic were susceptible to penicillin, a standard antimicrobial drug for the treatment of scarlet fever. However, >96% and [approximately equal to] 94% of the isolates were resistant to erythromycin and tetracycline, respectively, and [approximately equal to] 80% were resistant to clindamycin. These findings compare with earlier findings of 99.5%, 97.1%, and 99.5% resistance to erythromycin, tetracycline, and clindamycin, respectively (27). The extent of the resistance of GAS strains to erythromycin and tetracycline in many other countries has been very low (11,17,18). The high resistance rate in China might be attributed to the overuse of antimicrobial drugs in humans or animals.

In our study, the odds of having strawberry tongue or red rash with GAS infection was higher for younger patients. This could indicate that older patients had acquired partial immunity to GAS from a previous exposure or infection, resulting in milder clinical manifestation of the disease during subsequent infection.

This study had limitations. First, to track case outcomes, we followed up on the scarlet fever case-patients for 3 weeks after illness onset, which may not have allowed sufficient time to capture later-occurring complications; thus, outcome profiles may have been incomplete. Second, the enhanced surveillance in Beijing did not include invasive GAS diseases, so we could not report on all GAS strains circulating during the 2011 scarlet fever epidemic.

The 2011 scarlet fever epidemic in Beijing was characteristic of other scarlet fever epidemics and occurred after an abnormal peak winter incidence of the disease in 2010. emm12 type GAS became predominant. The level of GAS resistance to clindamycin was lower than that to erythromycin and tetracycline.

This study was supported by grants from the Beijing Nova Program of the Beijing Science and Technology Commission (2011047) and the National Key Program for Infectious Disease of China (2012ZX10004215-003-001).

References

(1.) Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13:470-511. http://dx.doi.org/10.1128/ CMR.13.3.470-511.2000

(2.) Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5:685-94. http://dx.doi.org/10.1016/S1473-3099(05)70267-X

(3.) Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective populationbased study. JAMA. 1993;269:384-9. http://dx.doi.org/10.1001/ jama.1993.03500030082037

(4.) Cone LA, Woodard DR, Schlievert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317:146-9. http:// dx.doi.org/10.1056/NEJM198707163170305

(5.) Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis. 2003;3:191-200. http:// dx.doi.org/10.1016/S1473-3099(03)00576-0

(6.) Whitnack E, Beachey EH. Inhibition of complement-mediated opsonization and phagocytosis of Streptococcus pyogenes by D fragments of fibrinogen and fibrin bound to cell surface M protein. J Exp Med. 1985;162:1983-97. http://dx.doi.org/10.1084/jem.162.6.1983

(7.) Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci U S A. 1988;85:1657-61. http://dx.doi.org/10.1073/pnas.85.5.1657

(8.) Dale JB, Penfound TA, Chiang EY, Walton WJ. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine. 2011;29:8175-8. http://dx.doi.org/10.1016/j.vaccine.2011.09.005

(9.) Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9:611-6. http://dx.doi.org/10.1016/S1473-3099(09)70178-1

(10.) Centers for Disease Control and Prevention. Introduction to emm typing: M protein gene (emm) typing Streptococcus pyogenes. 2008 [cited 2012 Apr 25]. http://www.cdc.gov/ncidod/biotech/strep/ M-ProteinGene_typing.htm

(11.) Meisal R, Andreasson IK, Hoiby EA, Aaberge IS, Michaelsen TE, Caugant DA. Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. J Clin Microbiol. 2010;48:842-51. http://dx.doi.org/10.1128/JCM.01312-09

(12.) O'Loughlin RE, Roberson A, Cieslak PR, Lynfield R, Gershman K, Craig A, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis. 2007;45:853-62. http://dx.doi. org/10.1086/521264

(13.) Ma Y, Yang Y, Huang M, Wang Y, Chen Y, Deng L, et al. Characterization of emm types and superantigens of Streptococcus pyogenes isolates from children during two sampling periods. Epidemiol Infect. 2009;137:1414-9. http://dx.doi.org/10.1017/S0950268809002118

(14.) Tewodros W, Kronvall G. M protein gene (emm type) analysis of group A beta-hemolytic streptococci from Ethiopia reveals unique patterns. J Clin Microbiol. 2005;43:4369-76. http://dx.doi. org/10.1128/JCM.43.9.4369-4376.2005

(15.) Fraser JD, Proft T. The bacterial superantigen and superantigen like proteins. Immunol Rev. 2008;225:226-43. http://dx.doi. org/10.1111/j.1600-065X.2008.00681.x

(16.) Sriskandan S, Faulkner L, Hopkins P. Streptococcus pyogenes: insight into the function of the streptococcal superantigens. Int J Biochem Cell Biol. 2007;39:12-9. http://dx.doi.org/10.1016/j. biocel.2006.08.009

(17.) Montes M, Ardanuy C, Tamayo E, Domenech A, Linares J, Perez-Trallero E. Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates. Eur J Clin Microbiol Infect Dis. 2011;30:1295-302. http://dx.doi.org/10.1007/s10096-011-1226-x

(18.) Tanz RR, Shulman ST, Shortridge VD, Kabat W, Kabat K, Cederlund E, et al. Community-based surveillance in the United States of macrolide-resistant pediatric pharyngeal group A streptococci during 3 respiratory disease seasons. Clin Infect Dis. 2004;39:1794-801. http://dx.doi.org/10.1086/426025

(19.) Liu X, Shen X, Chang H, Huang G, Fu Z, Zheng Y, et al. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. Pediatr Pulmonol. 2009;44:436-41. http://dx.doi.org/10.1002/ppul.20976

(20.) Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18:1096-100. http://dx.doi.org/10.1097/00006454-199912000-00014

(21.) Ministry of Health of China. Incidence of notifiable infectious diseases in China in May, 2011 [cited 2012 Apr 25]. http://www.moh.gov.cn/ publicfiles/business/htmlfiles/mohjbyfkzj/s3578/201106/52004.htm

(22.) Centers for Disease Control and Prevention. Streptococcus pyogenes emm sequence database. 2008 [cited 2012 Apr 25]. http://www.cdc. gov/ncidod/biotech/strep/protocol_emm-type.htm

(23.) Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-first international supplement M100-S21. Wayne (PA): The Institute; 2011.

(24.) Theresa Lamagni JD, George R, Efstratiou A. Analysis of epidemiological patterns during a century of scarlet fever. 2008 [cited 2012 Apr 25]. http://www.hpa.org.uk/webc/HPAwebFile/ HPAwebC/1229594253740

(25.) World Health Organization, Western Pacific Region. Scarlet fever: July 2011 [cited 2012 Apr 25]. http://www.wpro.who.int/mediacentre/factsheets/fs_20120301_ScarletFever/en/index .html

(26.) Liang Y, Shen X, Huang G, Wang C, Shen Y, Yang Y. Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. Acta Paediatr. 2008;97:1681-5. http://dx.doi. org/10.1111/j.1651-2227.2008.00983.x

(27.) Liang Y, Liu X, Chang H, Ji L, Huang G, Zhou F, et al. Epidemiological and molecular characteristics of clinical isolates of Streptococcus pyogenes from Chinese children between 2005 and 2008. J Med Microbiol. 2012;61:975-83. http://dx.doi.org/10.1099/ jmm.0.042309-0

(28.) Tse H, Bao JY, Davies MR, Maamary P, Tsoi HW, Tong AH, et al. Molecular characterization of the 2011 Hong Kong scarlet fever outbreak. J Infect Dis. 2012;206:341-51. http://dx.doi.org/10.1093/ infdis/jis362

(29.) Luk EY, Lo JY, Li AZ, Lau MC, Cheung TK, Wong AY, et al. Scarlet fever epidemic, Hong Kong, 2011. Emerg Infect Dis. 2012;18:1658-61. http://dx.doi.org/10.3201/eid1810.111900

(30.) Chen M, Yao W, Wang X, Li Y, Chen M, Wang G, et al. Outbreak of scarlet fever associated with emm12 type group A Streptococcus in 2011 in Shanghai, China. Pediatr Infect Dis J. 2012;31:e158-62. http://dx.doi.org/10.1097/INF.0b013e31825874f3

(31.) Shea PR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, et al. Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002-2010. Emerg Infect Dis. 2011;17:2010-7. http://dx.doi.org/10.3201/ eid1711.110159

(32.) Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A, et al. Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol.2009;47:1155-65. http://dx.doi.org/10.1128/JCM.02155-08

(33.) Commons R, Rogers S, Gooding T, Danchin M, Carapetis J, Robins-Browne R, et al. Superantigen genes in group A streptococcal isolates and their relationship with emm types. J Med Microbiol.2008;57:123:8- 46. http://dx.doi.org/10.1099/jmm.0.2008/001156-0

(34.) Rivera A, Rebollo M, Miro E, Mateo M, Navarro F, Gurgui M, et al. Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain. J Med Microbiol. 2006;55:1115-23. http://dx.doi.org/10.1099/jmm.0.46481-0

Address for correspondence: Quanyi Wang, Institute for Infectious Disease and Endemic Disease Control, Beijing Center for Disease Prevention and Control, No.16 He Pingli Middle St, Dongcheng District, Beijing 100013, China; email: bjcdcxm@126.com

Peng Yang, [1] Xiaomin Peng, [1] Daitao Zhang, Shuangsheng Wu, Yimeng Liu, Shujuan Cui, Guilan Lu, Wei Duan, Weixian Shi, Shuang Liu, Jing Li, and Quanyi Wang

Author affiliations: Beijing Center for Disease Prevention and Control, Beijing, China; and Capital Medical University School of Public Health, Beijing

DOI: http://dx.doi.org/10.3201/eid1906.121020

[1] These authors contributed equally to this article.

Dr Yang is an infectious disease epidemiologist at the Beijing Center for Disease Prevention and Control and at the School of Public Health and Family Medicine, Capital Medical University. His research interests are the surveillance of infectious diseases and early warning and intervention strategies for infectious diseases outbreaks.

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.
Table 1. SAgs and emm types of group A Streptococcus circulating
during a scarlet fever epidemic, Beijing, China, 2011 *

 No. (%) patients, by age
emm type [less than or >5 y, p
or SAg equal to] 5 y,
 n = 246 n = 401 value
emm type
 12 203 (82.5) 291 (72.6) 0.004#
 1 34 (13.8) 77 (19.2) 0.078
 Other 9 (3.7) 33 (8.2) 0.022#
 ([dagger])
SAg
 SpeA 47 (19.1) 96 (23.9) 0.15
 SpeB 246 (100.0) 401 (100.0) NA
 SpeC 243 (98.8) 400 (99.8) 0.156
 ([double dagger])
 SpeF 245 (99.6) 400 (99.8) 1
 ([double dagger])
 SpeG 246 (100.0) 399 (99.5) 0.528
 ([double dagger])
 SpeH 192 (78.0) 301 (75.1) 0.387
 SpeI 190 (77.2) 302 (75.3) 0.578
 SpeJ 47 (19.1) 92 (22.9) 0.249
 SpeK 1 (0.4) 3 (0.7) 1
 ([double dagger])
 SpeL 2 (0.8) 5 (1.2) 0.715
 ([double dagger])
 SpeM 5 (2.0) 9 (2.2) 0.857
 SmeZ 245 (99.6) 400 (99.8) 1
 ([double dagger])
 Ssa 241 (98.0) 391 (97.5) 0.705

 No. (%) patients, by sex
emm type Male, Female, p
or SAg
 n = 402 n = 245 value
emm type
 12 303 (75.4) 191 (78.0) 0.453
 1 73 (18.2) 38 (15.5) 0.386
 Other 26 (6.5) 16 (6.5) 0.975
 ([dagger])
SAg
 SpeA 91 (22.6) 52 (21.2) 0.675
 SpeB 402 (100.0) 245 (100.0) NA
 SpeC 398 (99.0) 245 (100.0) 0.303
 ([double dagger])
 SpeF 401 (99.8) 244 (99.6) 1
 ([double dagger])
 SpeG 400 (99.5) 245 (100.0) 0.529
 ([double dagger])
 SpeH 299 (74.4) 194 (79.2) 0.164
 SpeI 301 (74.9) 191 (78.0) 0.373
 SpeJ 87 (21.6) 52 (21.2) 0.9
 SpeK 1 (0.2) 3 (1.2) 0.155
 ([double dagger])
 SpeL 4 (1.0) 3 (1.2) 1.000
 ([double dagger])
 SpeM 8 (2.0) 6 (2.4) 0.697
 SmeZ 401 (99.8) 244 (99.6) 1.000
 ([double dagger])
 Ssa 394 (98.0) 238 (97.1) 0.477

 No. (%) patients,
 by clinical diagnosis
emm type Scarlet Pharyngitis, p Total,
or SAg fever,
 n = 430 n = 217 value n = 647
emm type
 12 331 (77.0) 163 (75.1) 0.599 494 (76.4)
 1 83 (19.3) 28 (12.9) 0.042# 111 (17.1)
 Other 16 (3.7) 26 (12.0) <0.001# 42 (6.5)
 ([dagger])
SAg
 SpeA 99 (23.0) 44 (20.3) 0.427 143 (22.1)
 SpeB 430 (100.0) 217 (100.0) NA 647 (100.0)
 SpeC 427 (99.3) 216 (99.5) 1.000 643 (99.4)
 ([double
 dagger])
 SpeF 429 (99.8) 216 (99.5) 1.000 645 (99.7)
 ([double
 dagger])
 SpeG 428 (99.5) 217 (100.0) 0.554 645 (99.7)
 ([double
 dagger])
 SpeH 326 (75.8) 167 (77.0) 0.747 493 (76.2)
 SpeI 327 (76.0) 165 (76.0) 1.000 492 (76.0)
 SpeJ 99 (23.0) 40 (18.4) 0.180 139 (21.5)
 SpeK 0 4 (1.8) 0.012# 4 (0.6)
 ([double
 dagger])
 SpeL 2 (0.5) 5 (2.3) 0.046# 7 (1.1)
 ([double
 dagger])
 SpeM 9 (2.1) 5 (2.3) 0.862 14 (2.2)
 SmeZ 428 (99.5) 217 (100.0) 0.554 645 (99.7)
 ([double
 dagger])
 Ssa 427 (99.3) 205 (94.5) <0.001# 632 (97.7)

* Boldface indicates statistical significance. SAg, superantigen.

([dagger]) Other emm types included types 4, 11, 22, 75, and 89.

([double dagger]) Fisher exact test was used.

Note: Boldface indicates statistical significance is indicated
with #.
COPYRIGHT 2013 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH
Author:Yang, Peng; Peng, Xiaomin; Zhang, Daitao; Wu, Shuangsheng; Liu, Yimeng; Cui, Shujuan; Lu, Guilan; Du
Publication:Emerging Infectious Diseases
Article Type:Report
Geographic Code:9CHIN
Date:Jun 1, 2013
Words:5089
Previous Article:Zoonotic Mycobacterium bovis-induced tuberculosis in humans.
Next Article:Transmission potential of Rift Valley fever virus over the course of the 2010 epidemic in South Africa.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters